Dulaglutide
Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes
Company n/r · Phase 3 · Completed · Enrollment 150
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Dulaglutide Group | n/r | n/r | n/r | n/r |
| Semaglutide Group | n/r | n/r | n/r | n/r |
| Tirzepatide Group | n/r | n/r | n/r | n/r |
Not shown
- Dulaglutide Group: endpoint not reported
- Semaglutide Group: endpoint not reported
- Tirzepatide Group: endpoint not reported